medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2009, Number 5

<< Back Next >>

Rev Mex Oftalmol 2009; 83 (5)

Bevacizumab intravítreo en retinopatía diabética proliferativa panfotocoagulada

Moreno-González ME

Language: Spanish
References: 11
Page: 281-283
PDF size: 107.13 Kb.


ABSTRACT

Purpose: To determine the presence of neovacularization after an intravitreal Bevacizumab injection in photocoagulated proliferative diabetic retinopathy. Patients and methods: Prospective, interventional and longitudinal study. Thirty three patients received intravitreal Bevacizumab injection (1.87 mg). Ophthalmic evaluations included searching disk and extra-disk neovascularization through three months. Results: Regression of neovascularization in 21 patients (63%) in the first week and 100% in the first month. Until the third month there was a recurrence of neovascularization in three patients. No adverse events were observed. Conclusions: Intravitreal Bevacizumab is an effective therapy in the regression of neovacularization in photocoagulated proliferative diabetic retinopathy; however more studies with more patients and longer follow up are needed.


REFERENCES

  1. Fong SD. Diabetic Retinopathy. Diabetes Care 2004; 27:2540-2553.

  2. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003; 52:506-511.

  3. Ferrara N. Vascular Endothelial Growth Factor. Basic Science and Clinical Progress Endocrine Reviews; 25(4):581-611.

  4. Hoeben A y cols. Vascular Endothelial Growth Factor and Angiogenesis. Pharmacol Rev 2004; 6:549-580.

  5. Augustin HG. Translating angiogenesis research into the clinic: the challenges ahead. Brit J Radiol 2003; 76:3-10.

  6. Gupta K. Angiogenesis: a curse or cure? Postgrad Med J 2005; 81:236-242.

  7. Kotoula MG. Metabolic Control of Diabetes Is Associated With an Improved Response of Diabetic Retinopathy to Panretinal Photocoagulation. Diabetes Care 2005; 28:2454-2457.

  8. Lin LP y cols. Plasma VEGF and Soluble VEGF Receptor FLT-1 in Proliferative Retinopathy: Relationship to Endothelial Dysfunction and Laser Treatment Invest Ophthalmol Vis Sci 2000; 41:2115-2119.

  9. Friedlander S. Vanishing disc neovascularization following Intravitreal Bevacizumab (Avastin) injection. Arch Ophthalmol 2006; 124:1365.

  10. Avery RL. Intravitreal Bevacizumab (Avastin) in the treatment of proliferative Diabetic retinopathy. Ophthalmology 2006; 113(103):1695.

  11. Mason OJ y cols. Intravitreal Bevacizumab (Avastin) in the treatment of proliferative Diabetic retinopathy. Am J Ophthalmol 2006; 142:685-688.




2020     |     www.medigraphic.com